Company profile: ArcherDX
1.1 - Company Overview
Company description
- Provider of NGS-based assay solutions advancing molecular pathology, using proprietary Anchored Multiplex PCR (AMP) chemistry and Archer Analysis software to detect genetic mutations for solid tumor, blood cancer, and genetic disease research. Offers VARIANTPlex DNA panels, FUSIONPlex RNA panels, LIQUIDPlex ctDNA panels, IMMUNOVerse immune profiling assays, and an Assay Marketplace for custom NGS panels.
Products and services
- NGS Assay Solutions: Delivers genomic information for solid tumors, blood cancers, immune profiling, and genetic disease research using Anchored Multiplex PCR chemistry and Archer Analysis software in an easy-to-use, lyophilized-format
- FUSIONPlex: Engineered RNA-based panels that detect known and novel gene fusions, splice variants, single nucleotide variants, insertions, deletions, and relative RNA expression for cancer research applications
- VARIANTPlex: DNA-based panels that detect single nucleotide variants, insertions, deletions, copy number variations, and microsatellite instability across various cancers for research use
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ArcherDX
NMS Group
HQ: Italy
Website
- Description: Provider of oncology research and development, managing the integrated R&D chain from pre-clinical to clinical stages. Operates a validated oncology drug discovery platform generating a pipeline of new chemical entities (NCEs).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NMS Group company profile →
Auron Therapeutics
HQ: United States
Website
- Description: Provider of cancer therapeutics focused on transforming malignant cells toward more normal function. Offerings include AURIGIN, an AI/ML platform to identify and target drivers of tumor cell plasticity and altered cellular states in cancer, and AUTX-703, an orally available small molecule therapy targeting KAT2A/B for small cell lung cancer, neuroendocrine prostate cancer, and acute myeloid leukemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Auron Therapeutics company profile →
Exai Bio
HQ: United States
Website
- Description: Provider of AI and machine learning-powered liquid biopsy tests that detect cancer-associated small non-coding RNA biomarkers (oncRNAs) in blood, enabling early detection, tissue-of-origin and subtype identification. Maintains a catalog of over 200,000 unique oncRNAs to support novel RNA-based tests, and partners with biopharma and healthcare to integrate RNA-based liquid biopsy into patient care and personalize treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exai Bio company profile →
Actuate Therapeutics
HQ: United States
Website
- Description: Provider of therapeutics and clinical research focused on elraglusib for high-impact cancers and neurodegenerative diseases, including adult and pediatric injection and oral tablet formulations for advanced, refractory solid and hematological cancers (e.g., pancreatic, metastatic melanoma, colorectal), combination regimens with chemotherapy, ongoing trials to assess efficacy and safety, and partnerships with academic and scientific organizations
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Actuate Therapeutics company profile →
Grey Wolf Therapeutics
HQ: United Kingdom
Website
- Description: Provider of antigen modulation therapies that control T cell activation by modulating antigen presentation. Offers ERAP1 and ERAP2 inhibition to generate and upregulate cancer antigens, MHCI-directed therapies to identify novel antigens, and GRWD5769, a selective ERAP1 inhibitor in EMITT-1, an adaptive Phase 1/2 clinical trial assessing monotherapy and combinations with anticancer treatments in solid malignancies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Grey Wolf Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ArcherDX
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ArcherDX
2.2 - Growth funds investing in similar companies to ArcherDX
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ArcherDX
4.2 - Public trading comparable groups for ArcherDX
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →